Vol. 1 No. 8 (2021)
Reimbursement Reviews

Patiromer (Veltassa)

Published August 4, 2021

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses patiromer (Veltassa), 8.4 g, 16.8 g, 25.2 g patiromer (as patiromer sorbitex calcium) and patiromer powder for oral suspension.
  • Indication: For the treatment of hyperkalemia in adults with chronic kidney disease (estimated glomerular filtration rate ≥ 15 mL/min/1.73 m2).
  • Reimbursement request: For the treatment of hyperkalemia in patients with chronic kidney disease 3 to 4 on renin-angiotensin-aldosterone system inhibitor therapy.